Trial Profile
A Phase II, Open Label Study Evaluating an Alternative Schedule of Velcade/Dexamethasone Plus Doxil in the Treatment of Multiple Myeloma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Doxorubicin liposomal (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 05 Apr 2012 Actual patient number changed from 33 to 32 as reported by ClinicalTrials.gov.
- 18 Aug 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 20 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.